SC hereby invites grant applications for support under the Early Career Research Program in the following program areas: Advanced Scientific Computing Research (ASCR); Biological and Environmental Research (BER); Basic Energy Sciences (BES), Fusion Energy Sciences (FES); High Energy Physics (HEP), and Nuclear Physics (NP). The purpose of this program is to support the development of individual research programs of outstanding scientists early in their careers and to stimulate research careers in the areas supported by SC.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of cancer, environmental health, heart disease, blood disorders, diseases of the eye and visual system, mental health, and neurological disorders. Partnering U.S. and Chinese investigators must work jointly to submit identical applications to NIH and National Natural Science Foundation of China (NSFC), respectively. U.S. investigators must respond to the announcement from NIH, including the Chinese application as an attachment, and Chinese investigators must respond to a separate funding announcement from NSFC, including the NIH application as an attachment.

To that end, the foundation is accepting Letters of Intent for its Hollis Brownstein Research Grants Program. Through the program, one-year grants of $100,000 will be awarded in support of innovative blood cancer research projects headed up by early-career scientists. Priority will be given to proposals that focus on leukemia, lymphoma, MDS, and multiple myeloma.

The NIH Research Evaluation and Commercialization Hub (REACH) program is envisioned as a partnership program between NIH and the qualifying research institutions to accelerate the creation of small businesses and the transition of discoveries originating from academic research into products that improve health. REACH Hubs will foster the advancement of therapeutics, preventatives, diagnostics, devices, and tools in a manner consistent with business case development, that address the needs of patients and public health.

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.    

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing may be available for tumor or affected tissue when justified. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

ACS is keenly interested in supporting rapid-learning research on the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to facilitators and barriers to care; unintended consequences; differential experiences of and outcomes for patients seeking or receiving care; best practice models for quality care; and economic Impact.

This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the PS-OPs is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming small transdisciplinary teams of physical scientists and cancer biologists/physician-scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.

The purpose of this Funding Opportunity Announcement (FOA) is to promote collaborative biomedical research between the United States and Brazil under the U.S.-Brazil Biomedical Collaborative Research Program. Research areas supported under this program include allergy, immunology, and infectious diseases, including HIV/AIDS and its co-morbidities; cancer; mother-to-child transmission of HIV and other congenital infections, early infant diagnosis and treatment; HIV/AIDS in relation to mental health; and neurological disorders and stroke.

This year, PCAN has partnered with the Celgene Corporation to accelerate the development of novel therapies by establishing strong relationships between academia and industry through research grants. Funded projects will benefit from industry input and insight, leading to an accelerated translation to a therapeutic product. Projects should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance. Of particular interest are projects that fall into at least one of these three areas of research: a) immune context and tumor micro-environment interactions; (b) regulators of pathogenesis, progression, and metabolism, with particular interest in epigenetic mechanisms; and (c) transcriptional networks essential for viability and maintenance of malignant phenotype.

REISSUE of PAR-18-733 The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

The purpose of this FOA is to promote the development of advanced research centers that can build capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities. The Implementation Science Centers in Cancer Control (ISCCC) Program will support the rapid development, testing, and refinement of innovative approaches to implementing a range of evidence-based cancer control interventions, establish implementation laboratories from existing clinical and community sites providing services across the cancer control continuum, advance methods in studying implementation, develop and validate reliable measures of key implementation science constructs, and together form a large consortium of implementation scientists across this and other Moonshot initiatives. The ISCCC Program will support P50 Advanced Centers (under this FOA) and P50 Developing Centers (companion RFA-CA-19-005).

The purpose of this FOA is to promote the creation of developing research centers that can build capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities. The Implementation Science Centers in Cancer Control (ISCCC) Program will support the rapid development, testing and refinement of innovative approaches to implementing a range of evidence-based cancer control interventions, establish implementation laboratories from existing clinical and community sites providing services across the cancer control continuum, advance methods in studying implementation, develop and validate reliable measures of key implementation science constructs, and together form a large consortium of implementation scientists across this and other Moonshot initiatives. The ISCCC Program will support P50 Developing Centers (under this FOA) and P50 Advanced Centers (companion RFA-CA-19-006).

The Miami Initiative for Advancing, Mentoring and Investing in Women (M.I.A.M.I. WOMEN) awarded nearly $104,000 in Giving Circle grants to students and faculty during the annual Leadership Symposium on April 12, 2018. Finalists pitched their projects the previous evening at the inaugural Hawk Tank event. This grant fund is open again for the 2018-2019 cycle.

The CDC, Division of Cancer Prevention and Control (DCPC) announces the availability of Fiscal Year 2019 funds to implement DP19-1905, The CDC Cancer Genomics Program: Translating Research into Public Health Practice. This program addresses the utilization of cancer genetic services as a strategy for cancer prevention and control. The primary outcomes of this NOFO are to increase screening of cancer family history and to increase the use of genetic counseling and testing for Hereditary Breast and Ovarian Cancer (HBOC) and Lynch Syndrome (LS) among individuals meeting recommendations for referral. This funding opportunity supports the implementation and evaluation of public health activities within four core strategies to build the evidence base and disseminate best practices. These priorities will be accomplished by funding up to 5 awardees to develop, implement, and evaluate state-level programs in cancer genomics. Funding will support applicants that demonstrate: Appropriate experience with surveillance systems, partners and similar work in cancer genomics Appropriate organizational capacity to perform, implement, and evaluate activities and strategies An approach that is consistent with the strategies and outcomes described in the NOFO An ability to collect data towards key performance measures and outcomes Innovative methods and approaches to program and strategy implementation

The proposed program's purpose is to increase the availability of supportive services for young breast cancer survivors (YBCS), young women with metastatic breast cancer (mBC), and their caregivers and families by supporting organizations and entities that serve this population. The awardees will address strategies relevant to the target audience. These include: the establishment of a network of survivors and caregivers to facilitate policy, system, and environmental change interventions that increases access to lifestyle programs, clinical preventive services, and cancer care among survivors; development and implementation of innovative technological educational opportunities for health care providers on topics relevant to the delivery of appropriate treatment and care of YBCS and mBC; and utilization of patient navigation and community health worker program strategies to reach underserved populations to enhance their access to and utilization of YBCS services and programs. To this end, activities funded by this NOFO, are intended to support organizations in closing the disparity gap needed to support young breast cancer survivors. Specifically, organizations will implement strategies that aim to reduce disparities observed in survival and quality of life due to race, ethnicity, or other social determinants of health. This NOFO will also support organizations in providing support services/programs to YBCS and mBC; and provide resources for health care providers in caring for all YBCS and mBC regardless of race, ethnicity, age, or sexual orientation during the period of performance of 09/30/2019-09/22/2024.

 This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.